Moderna's post-pandemic reinvention hinges on cancer vaccines succeeding where flu shots haven't
Moderna's stock and revenue have spent several years coming down from the extraordinary highs of the COVID-19 vaccine boom, and the company's strategic story has narrowed to a single question that matters more than any quarterly earnings print: can its mRNA platform, which proved itself against a vi
Source: Reuters